Brief: Decibel Therapeutics Submits Clinical Trial Applications For Lead Gene Therapy Candidate
02/11/2022 11:18
Nov 2 (Reuters) - Decibel Therapeutics Inc DBTX.O :
* DECIBEL THERAPEUTICS ANNOUNCES SUBMISSION OF CLINICAL
TRIAL
APPLICATIONS FOR LEAD GENE THERAPY CANDIDATE DB-OTO
* DECIBEL THERAPEUTICS - SUBMISSION OF CLINICAL TRIAL
APPLICATIONS
MHRA IN UK AND AEMPS FOR A PHASE 1/2 CLINICAL TRIAL IN PEDIATRIC
PATIENTS OF DB-OTO
Source text for Eikon: ID:nGNXB6fcJ
Further company coverage: DBTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Decibel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Domo, BlackBerry, Rite Aid
U.S. STOCKS ON THE MOVE-Decibel Therapeutics, Affirm Holdings, Medtronic
Decibel rises on FDA's 'fast-track' tag for hearing-loss therapy
Brief: Decibel Therapeutics Says US Food And Drug Administration Had Granted Fast Track Designation For DB-OTO
Decibel Therapeutics Inc reports results for the quarter ended in June - Earnings Summary